跳至主要内容
临床试验/NCT00348569
NCT00348569已完成不适用

A Prospective, Multicenter Study of GE LightSpeed Volume Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain Patients Suspected of Coronary Artery Disease

GE Healthcare2 个研究点 分布在 1 个国家目标入组 245 人开始时间: 2006年5月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
GE Healthcare
入组人数
245
试验地点
2

研究概览

简要总结

To compare computed tomography (CT) images (pictures) of the coronary arteries using the General Electric (GE) LightSpeed VCT scanner with x-ray coronary angiography in patients with typical or atypical chest pain suspected of coronary artery disease (CAD).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The subject has typical or atypical chest pain suspected of CAD and is referred for an elective coronary angiography.
  • The subject must be scheduled to undergo a CATH procedure between 48 hours and 3 weeks post CCTA procedure.
  • The subject must not undergo any cardiac interventional treatment between the 2 procedures.
  • The subject must have sinus rhythm with stable heart rate of ≤65 beats per minute (bpm) or if heart rate was >65 bpm, the subject must agree to the use of beta-blocker(s) prior to the CT scan procedure to achieve stable heart rate of ≤65 bpm.

排除标准

  • The subject had an established diagnosis of CAD by a) previous CATH, b) prior myocardial infarction confirmed by ECG, or c) prior revascularization (balloon angioplasty, stent placement, or CABG).
  • The subject had a known allergy to iodinated contrast agent, including but not limited to hives, anaphylactoid or cardiovascular reactions, laryngeal edema and bronchospasm.
  • The subject had impaired renal function with a serum creatinine level of 1.7 mg/dL (150 μmol/L) or above.
  • The subject had atrial fibrillation/flutter or any irregular heart rhythm considered by the investigator to interfere with temporal acquisition of cardiac CT images.
  • The subject had a resting heart rate of >100 bpm and/or a resting systolic blood pressure of <100mm Hg.
  • The subject had an artificial heart valve(s).
  • The subject has had prior pacemaker or internal defibrillator lead implantation.
  • The subject's resting heart rate was >65 bpm and beta-blocker therapy was contraindicated.
  • The subject had a contraindication to verapamil when beta-blocker therapy could not be administered. The subject had a contraindication to nitroglycerin.
  • The subject had evidence of ongoing or active clinical instability.

研究组 & 干预措施

64 Channel VCT

Experimental

All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed 2 to 21 days later by catheter coronary angiography (CATH).

干预措施: 64 Channel VCT (Device)

研究者

发起方
GE Healthcare
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验